GlassScriptPhysician profile
Gabriel H Domenech
NPI 1427043785
$19,524.30
in general payments reported to CMS, 2019-2025
85 companies · $3,802 in 2025
The $3,802 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $1,737 · 2021: $1,550 · 2022: $2,049 · 2023: $3,533 · 2024: $4,755 · 2025: $3,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $299 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,549.03 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $242.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,721.24 | 2019-2025 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $1,486.96 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,356.13 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Pfizer INC. | $1,351.63 | 2019-2025 | |
| Janssen Biotech, INC. | $1,323.19 | 2019-2025 | Darzalex, Rybrevant, Erleada |
| E.R. Squibb & Sons, L.L.C. | $1,131.12 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Genentech USA, INC. | $629.20 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Daiichi Sankyo INC. | $621.86 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $496.49 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $484.61 | 2019-2025 | |
| Seagen INC. | $422.14 | 2019-2024 | Tukysa, Tivdak, Padcev |
| Taiho Oncology, INC. | $341.42 | 2019-2025 | |
| Array Biopharma INC | $338.75 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Celgene Corporation | $332.39 | 2019-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $326.44 | 2022-2025 | Venclexta |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $325.84 | 2019-2025 | Libtayo, Lynozyfic |
| Amgen INC. | $307.85 | 2019-2025 | Kyprolis |
| Kite Pharma, INC. | $293.75 | 2020-2025 | Yescarta |
| Coherus Oncology, INC. | $289.25 | 2020-2025 | Udenyca, Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $263.72 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $216.26 | 2021-2025 | Myrisk |
| Tempus Ai, INC | $215.21 | 2024-2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $213.27 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Exelixis INC. | $212.31 | 2020-2025 | Cabometyx |
| Emd Serono, INC. | $209.41 | 2019-2025 | Bavencio |
| Takeda Pharmaceuticals U.S.A., INC. | $207.70 | 2022-2025 | Ninlaro, Alunbrig, Iclusig |
| Astellas Pharma US INC | $185.20 | 2019-2024 | Padcev, Vyloy, Xospata |
| Incyte Corporation | $182.48 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Deciphera Pharmaceuticals INC. | $175.00 | 2021-2024 | Qinlock |
| Eisai INC. | $164.56 | 2019-2025 | |
| Advanced Accelerator Applications | $157.87 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $152.73 | 2024-2025 | |
| Sirtex Medical INC | $148.03 | 2019-2023 | Sir-Spheres Microspheres |
| Tersera Therapeutics LLC | $147.09 | 2023-2025 | Zoladex |
| Pharmaessentia USA Corporation | $141.98 | 2022-2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $135.89 | 2023-2025 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $125.52 | 2019-2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $120.47 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $119.66 | 2022-2025 | Ultomiris |
| Kyowa Kirin, INC. | $118.92 | 2022-2023 | Poteligeo |
| Adaptive Biotechnologies Corporation | $116.84 | 2022-2023 | Clonoseq |
| Blue Earth Diagnostics | $116.27 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $111.35 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $110.82 | 2019-2025 | Onivyde, Somatuline Depot |
| Dendreon Pharmaceuticals LLC | $105.80 | 2019-2025 | Provenge |
| Stemline Therapeutics INC. | $104.28 | 2024-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $98.16 | 2021-2024 | |
| Foundation Medicine, INC. | $96.64 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $96.21 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $94.53 | 2020-2024 | Xpovio |
| Mirati Therapeutics, INC. | $91.88 | 2023-2024 | Krazati |
| Beigene USA, INC. | $71.63 | 2022-2024 | Brukinsa |
| Janssen Pharmaceuticals, INC | $65.41 | 2020-2021 | |
| Puma Biotechnology, INC. | $58.28 | 2019-2025 | |
| Beone Medicines USA, INC. | $56.48 | 2025 | Tevimbra, Brukinsa |
| Dova Pharmaceuticals | $56.46 | 2019-2021 | |
| Adc Therapeutics America, INC. | $56.02 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.02 | 2024-2025 | |
| Gilead Sciences, INC. | $48.53 | 2019 | |
| Blueprint Medicines Corporation | $47.22 | 2020-2025 | Ayvakit |
| Cti Biopharma Corp. | $46.66 | 2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $44.16 | 2024-2025 | Vivimusta |
| Genmab U.S., INC. | $42.86 | 2023-2024 | Epkinly |
| Mylan Institutional INC. | $42.72 | 2022-2023 | Fulphila, Ogivri |
| Pharmaand Gmbh | $42.26 | 2025 | Rubraca |
| Tolmar, INC. | $39.99 | 2025 | Rubraca, Eligard |
| Ge Healthcare | $32.34 | 2025 | |
| Rigel Pharmaceuticals, INC. | $30.45 | 2023 | Rezlidhia, Tavalisse |
| Legend Biotech USA INC. | $29.19 | 2025 | Carvykti |
| Caris Mpi, INC. | $28.55 | 2025 | Mi Cancer Seek |
| Janssen Scientific Affairs, LLC | $27.31 | 2019 | |
| Epizyme, INC. | $24.94 | 2022 | |
| Octapharma USA, INC. | $24.91 | 2020 | |
| Novocure INC. | $24.78 | 2025 | Optune Lua (Novottf-200t) |
| Biocon Biologics INC | $24.10 | 2024 | Fulphila |
| Tolmar Pharmaceuticals, INC. | $23.46 | 2019 | |
| Boston Scientific Corporation | $21.87 | 2024 | Spaceoar Vue System - 10ml |
| Amneal Pharmaceuticals LLC | $21.54 | 2025 | Alymsys |
| Sobi, INC | $20.23 | 2024 | |
| Fennec Pharmaceuticals, INC. | $19.36 | 2024 | Pedmark |
| Clovis Oncology, INC. | $17.24 | 2021 | |
| Sumitomo Pharma America, INC. | $16.70 | 2024 | Orgovyx |
| Heron Therapeutics, INC. | $15.77 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.54 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $934Lynparza $573Kisqali $536Enhertu $374Opdivo $337Ibrance $308Tukysa $308Braftovi $286Darzalex $275Udenyca $265Jaypirca $260Verzenio $260Pluvicto $259Xtandi $257Libtayo $253Piqray $247Imfinzi $242Venclexta $240Mektovi $236Talzenna $218Xt Cdx $215Xofigo $215Nubeqa $215Elrexfio $204Adcetris $193Inqovi $192Lonsurf $192Padcev $186Lorbrena $186Imbruvica $182Welireg $174Inlyta $165Orgovyx $161Tagrisso $161Zepzelca $153Zoladex $147Jakafi $140Rybrevant $137Monoferric $136Reblozyl $133Tecentriq $130Qinlock $126Myrisk $124Lenvima $123Erleada $120Krazati $111Retevmo $109Orserdu $104Posluma $103Cabometyx $102Lutathera $102Bavencio $102Paxlovid $101Tecvayli $100Tivdak $99.25Idhifa $96.67Bosulif $95.67Ultomiris $95.61Tibsovo $95.49Besremi $94.81Axumin $93.76Ojjaara $87.71Sarclisa $85.78Rubraca $82.25Comirnaty $81.15Elahere $80.97Provenge $80.56Talvey $77.41Yescarta $76.92Brukinsa $75.98Odomzo $75.70Clonoseq $75.63Opdualag $72.71Poteligeo $72.10Epkinly $68.78Calquence $65.84Polivy $57.87Xalkori $55.43Xpovio $55.13Datroway $54.55Phesgo $50.61Zynyz $49.92Besponsa $49.29Ninlaro $48.20Alunbrig $48.09Fulphila $48.03Fabhalta $47.63Jemperli $47.59Zejula $47.59Vonjo $46.66Onivyde $45.01Yonsa $44.44Vivimusta $44.16Nerlynx $43.35Tevimbra $34.56Tecentriq Hybreza $33.28Rezlidhia $30.45Tavalisse $30.45Iclusig $29.43Carvykti $29.19
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Domenech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.